CytomX Therapeutics (CTMX) EBT (2014 - 2026)

CytomX Therapeutics has reported EBT for 13 years, with the latest figure at -$18.2 million in Q1 2026.

• For the quarter ending Q1 2026, EBT fell 177.11% year-over-year to -$18.2 million; the trailing twelve-month figure through Mar 2026 stood at -$58.9 million (down 240.79% YoY), and the FY2025 full-year result was -$17.1 million, down 153.38% from the prior year.
• EBT for Q1 2026 stood at -$18.2 million, up from -$26.5 million in the prior quarter.
• The five-year high for EBT was $23.6 million in Q1 2025, with the low at -$32.0 million in Q1 2022.
• Historically, EBT has averaged -$5.8 million across 5 years, with a median of -$3.3 million in 2023.
• The largest YoY upside for EBT was 893.6% in 2024 against a maximum downside of 496.41% in 2024.
• CytomX Therapeutics' EBT stood at -$8.8 million in 2022, then surged by 121.72% to $1.9 million in 2023, then soared by 893.6% to $18.9 million in 2024, then plunged by 239.7% to -$26.5 million in 2025, then surged by 31.25% to -$18.2 million in 2026.
• The last three EBT figures came in at -$18.2 million (Q1 2026), -$26.5 million (Q4 2025), and -$14.2 million (Q3 2025), per Business Quant data.